An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Robert WilcoxFaculty of Medicine & Health Sciences, Cardiovascular Medicine, Queens Medical Centre NottinghamUKCorrespondence[email protected]

Kamran IqbalDaiichi Sankyo UK Ltd Gerrards Cross, BuckinghamshireUK

Tim CostiganLilly Research Laboratories Indianapolis, INUSA

Jose Lopez-SendonHospital Universitario La Paz, IdiPaz, Universidad Autonoma de Madrid MadridSpain

Yvonne RamosDaiichi Sankyo Europe GmbH MunichGermany

Petr WidimskyCharles University Prague, University Hospital Kralovske Vinohrady PragueCzech Republic

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Patrizia Natale, Suetonia C Palmer, Valeria M Saglimbene, Marinella Ruospo, Mona Razavian, Jonathan C Craig, Meg J Jardine, Angela C Webster & Giovanni FM Strippoli. (2022) Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2022:2.
Crossref

Kalpa De Silva, Divaka Perera & Peter O'Kane. 2018. Cardiovascular Thrombus. Cardiovascular Thrombus 123 146 .

Kalpa De Silva, Aung Myat, James Cotton, Stefan James, Anthony Gershlick & Gregg W Stone. (2017) Bleeding associated with the management of acute coronary syndromes. Heart 103:7, pages 546-562.
Crossref

Masakatsu Nishikawa, Takaaki Isshiki, Takeshi Kimura, Hisao Ogawa, Hiroyoshi Yokoi, Shunichi Miyazaki, Yasuo Ikeda, Masato Nakamura, Yuko Tanaka & Shigeru Saito. (2017) Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies. Cardiovascular Intervention and Therapeutics 32:2, pages 93-105.
Crossref

José Ramón González-Juanatey, Rosa Agra Bermejo & José López-Sendón. (2017) Una historia resumida. Impacto de los avances en cardiopatía isquémica. Revista Española de Cardiología Suplementos 17, pages 2-6.
Crossref

Nicolas Danchin, Maddalena Lettino, Uwe Zeymer, Petr Widimsky, Alfredo Bardaji, Jose A. Barrabes, Angel Cequier, Marc J. Claeys, Leonardo De Luca, Jakob Dörler, David Erlinge, Paul Erne, Patrick Goldstein, Sasha M. Koul, Gilles Lemesle, Thomas F. Lüscher, Christian M. Matter, Gilles Montalescot, Dragana Radovanovic, Jose Lopez Sendón, Petr Tousek, Franz Weidinger, Clive F. M. Weston, Azfar Zaman, Pontus Andell, Jin Li & J. Wouter Jukema. (2016) Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy 2:3, pages 152-167.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Citations (6)

Articles from other publishers (6)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date